|
2015 Conference Publication Systemic treatments in melanoma influence the accessibility of the immune system to the tumor: A retrospective histopathological investigationKraehenbuehl, L., Goldinger, S. M., Matsushita, S., Amann, V. C., Kempf, W., Levesque, M. P. and Dummer, R. (2015). Systemic treatments in melanoma influence the accessibility of the immune system to the tumor: A retrospective histopathological investigation. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Journal Article Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitorGalliker, Nadja A., Murer, Carla, Kamarashev, Jivko, Dummer, Reinhard and Goldinger, Simone M. (2015). Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. European Journal of Dermatology, 25 (2), 177-180. doi: 10.1684/ejd.2014.2512 |
|
2015 Journal Article A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanomaGoldinger, Simone M., Rinderknecht, Jeannine, Dummer, Reinhard, Kuhn, Felix Pierre, Yang, Kuo-Hsiung, Lee, Lucy, Ayala, Ruben C., Racha, Jagdish, Geng, Wanping, Moore, David, Liu, Mei, Joe, Andrew K., Bazan, Selby Patricia Gil and Grippo, Joseph F. (2015). A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacology Research & Perspectives, 3 (2) e00113. doi: 10.1002/prp2.113 |
|
2015 Journal Article Curing advanced melanoma by 2025Dummer, Reinhard, Goldinger, Simone M., Paulitschke, Verena and Levesque, Mitchell P. (2015). Curing advanced melanoma by 2025. Current Opinion in Oncology, 27 (2), 125-127. doi: 10.1097/CCO.0000000000000168 |
|
2015 Journal Article Methylation-dependent <i>SOX9</i> expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanomaCheng, Phil F., Shakhova, Olga, Widmer, Daniel S., Eichhoff, Ossia M., Zingg, Daniel, Frommel, Sandra C., Belloni, Benedetta, Raaijmakers, Marieke I. G., Goldinger, Simone M., Santoro, Raffaella, Hemmi, Silvio, Sommer, Lukas, Dummer, Reinhard and Levesque, Mitchell P. (2015). Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology, 16 42. doi: 10.1186/s13059-015-0594-4 |
|
2014 Journal Article Basal cell carcinomas in a tertiary referral centre: a systematic analysisDreier, J., Cheng, P. F., Alleman, I. Bogdan, Gugger, A., Hafner, J., Tschopp, A., Goldinger, S. M., Levesque, M. P. and Dummer, R. (2014). Basal cell carcinomas in a tertiary referral centre: a systematic analysis. British Journal of Dermatology, 171 (5), 1066-1072. doi: 10.1111/bjd.13217 |
|
2014 Journal Article Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous <i>t</i>-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome)Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E. A., Rozati, S., Eggmann, N., Goldinger, S. M., Hutchinson, K., Geskin, L., Illidge, T. M., Giuliano, E., Elder, J. and Kim, Y. H. (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome). Annals of Oncology, 25 (9), 1807-1812. doi: 10.1093/annonc/mdu231 |
|
2014 Conference Publication Association of leukocyte counts and adverse events in BRAF inhibitor-treated patientsCosgarea, I., Sondermann, W., Livingstone, E., Griewank, K., Weide, B., Loquai, C., Hassel, J., Kaehler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Schadendorf, D., Zimmer, L. and Schilling, B. (2014). Association of leukocyte counts and adverse events in BRAF inhibitor-treated patients. HOBOKEN: WILEY-BLACKWELL. |
|
2014 Conference Publication Immunreactivity for CTLA-4 in anterior pituitary gland cells and neutrophils suggest antibody dependent cytotoxicity to trigger Ipilimumab induced hypophysitisBjasch, D., Maggio, E. Marquez, Fitsche, A., Moch, H., Goldinger, S. M., Dummer, R. and Mihic-Probst, D. (2014). Immunreactivity for CTLA-4 in anterior pituitary gland cells and neutrophils suggest antibody dependent cytotoxicity to trigger Ipilimumab induced hypophysitis. NEW YORK: SPRINGER. |
|
2014 Journal Article Transient MEK inhibitor-associated retinopathy in metastatic melanomaUrner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Moutouh-de Parseval, L., Dummer, R. and Goldinger, S. M. (2014). Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Annals of Oncology, 25 (7), 1437-1441. doi: 10.1093/annonc/mdu169 |
|
2014 Journal Article To B-(RAF) or Not to BeDummer, Reinhard, Goldinger, Simone M., Widmer, Daniel, Dreier, Jil and Levesque, Mitchell P. (2014). To B-(RAF) or Not to Be. Journal of Investigative Dermatology, 134 (5), 1200-1201. doi: 10.1038/jid.2014.62 |
|
2014 Journal Article Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaSchilling, B., Sondermann, W., Zhao, F., Griewank, K. G., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kahler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2014). Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 25 (3), 747-753. doi: 10.1093/annonc/mdt587 |
|
2014 Conference Publication Differential influence of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical efficacy in melanomaSchilling, B., Sondermann, W., Zhao, F., Griewank, K., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J. C., Kaehler, K. C., Utikal, J., Al Ghazal, P., Gutzmar, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2014). Differential influence of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical efficacy in melanoma. 41st Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung (ADF), Cologne Germany, Mar 13-15, 2014. HOBOKEN: WILEY. |
|
2014 Journal Article Vemurafenib in patients with <i>BRAF<SUP>V600</SUP></i> mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot studyDummer, Reinhard, Goldinger, Simone M., Turtschi, Christian P., Eggmann, Nina B., Michielin, Olivier, Mitchell, Lada, Veronese, Luisa, Hilfiker, Paul Rene, Felderer, Lea and Rinderknecht, Jeannine D. (2014). Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. European Journal of Cancer, 50 (3), 611-621. doi: 10.1016/j.ejca.2013.11.002 |
|
2014 Journal Article The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic MelanomaVan Allen, Eliezer M., Wagle, Nikhil, Sucker, Antje, Treacy, Daniel J., Johannessen, Cory M., Goetz, Eva M., Place, Chelsea S., Taylor-Weiner, Amaro, Whittaker, Steven, Kryukov, Gregory V., Hodis, Eran, Rosenberg, Mara, McKenna, Aaron, Cibulskis, Kristian, Farlow, Deborah, Zimmer, Lisa, Hillen, Uwe, Gutzmer, Ralf, Goldinger, Simone M., Ugurel, Selma, Gogas, Helen J., Egberts, Friederike, Berking, Carola, Trefzer, Uwe, Loquai, Carmen, Weide, Benjamin, Hassel, Jessica C., Gabriel, Stacey B., Carter, Scott L. ... Schadendorf, Dirk (2014). The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discovery, 4 (1), 94-109. doi: 10.1158/2159-8290.CD-13-0617 |
|
2014 Journal Article Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsGoldinger, Simone M., Zimmer, Lisa, Schulz, Carsten, Ugurel, Selma, Hoeller, Christoph, Kaehler, Katharina C., Schadendorf, Dirk, Hassel, Jessica C., Becker, Juergen, Hauschild, Axel and Dummer, Reinhard (2014). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 50 (2), 406-410. doi: 10.1016/j.ejca.2013.09.014 |
|
2013 Conference Publication Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutationsGoldinger, Simone M., Murer, Carla, Stieger, Pascale and Dummer, Reinhard (2013). Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutations. European Cancer Congress, Amsterdam, Netherlands, 27 September - 1 October 2013. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.ejcsup.2013.07.011 |
|
2013 Conference Publication Differential effects of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical effectivity in melanomaSchilling, B., Suttorp, W., Zhao, F., Griewank, K., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kaehler, K., Utikal, J., Gutzmer, R., Al Ghazal, P., Goldinger, S., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2013). Differential effects of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical effectivity in melanoma. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication Registry for advanced melanoma in SwitzerlandMangana, J., Frauchiger, A., Goldinger, S. M., Gautschi, M., Von Moos, R., Romano, E., Michielin, O., Levesque, M. P. and Dummer, R. (2013). Registry for advanced melanoma in Switzerland. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Conference Publication Hyponatraemia and Tachyarrhythmia During Ipilimumab: Lessons from the AutopsyMurer, C., Goldinger, S. M., Maggio, Marques E., Bjasch, D., Stieger, P., Mihic-Probst, D., Schad, K. and Dummer, R. (2013). Hyponatraemia and Tachyarrhythmia During Ipilimumab: Lessons from the Autopsy. HOBOKEN: WILEY-BLACKWELL. |
